

研究成果の刊行に関する一覧表

【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
長谷川稔	硬化性苔癬	高橋健造 佐伯秀久	皮膚疾患 最新の治療 2023-2024	㈱南江堂	日本	2023	111
浅野善英	【これ1冊！皮膚科領域における膠原病診療の極意】強皮症の診断と治療の極意	茂木精一郎	Derma	全日本病院出版会	日本	2022	1-10
大竹里奈、沖山奈緒子	限局性強皮症の診断と治療の極意	茂木精一郎	MB Derma No. 326	全日本病院出版会	日本	2022	19-25
川口鎮司	多発性筋炎、皮膚筋炎	門脇 孝 小室一成 宮地良樹	治療ガイドライン UP-TO-DATE 2022- 2023	メディカルレビュー社	日本	2022	659-665
長谷川稔	リウマチ性疾患の皮膚病変のみかた	日本リウマチ財団教育研修委員会 日本リウマチ学会生涯教育委員会	リウマチ病学 テキスト	㈱南江堂	日本	2022	68-75
長谷川稔	レイノー現象をきたす疾患	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	35-36
長谷川稔	全身性強皮症	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	405-408
長谷川稔	限局性強皮症	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	408-409
尾山徳孝、長谷川稔	硬化性苔癬	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	775-777
茂木精一郎	これ1冊！皮膚科領域における膠原病診療の極意	茂木精一郎	Dermaこれ1冊！皮膚科領域における膠原病診療の極意	全日本病院出版会	日本	2022	1
茂木精一郎	ステロイド投与の対象となる強皮症は？	宮地良樹 常深祐一郎	皮膚科診療 Controversy	中外医学社	日本	2022	181-184
茂木精一郎	強皮症	神人正寿 常深祐一郎	皮膚科診療秘伝の書	南江堂	日本	2022	72-79

【雑誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kubota N, Tanaka R, Ichimura Y, Konishi R, Tso JY, Tsurushita N, Nomura T, Okiyama N	Blockade of CD122 on memory T cells in the skin suppresses sclerodermatous graft-versus-host disease.	J Dermatol Sci.	Online		2023
<u>Kuwana M</u> , Bando M, Kawahito Y, Sato S, Suda T, and Kondoh Y	Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements	Expert Rev Respir Med	doi: 10.1080/17476348.2023.2176303	Online ahead of print	2023
<u>Kuwana M</u> , Abe K, Kinoshita K, Matsubara H, Minatsuki S, Murohara T, Sakao S, Shirai Y, Tahara N, Tsujino I, Takahashi K, Kanda S, and Ogo T	Efficacy, safety and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension	Pulm Circ	13	e12198	2023
Khanna D, Maher TM, Volkmann ER, Allanore Y, Smith V, Assassi S, Kreuter M, Hoffmann-Vold AM, <u>Kuwana M</u> , Stock C, Alves M, Sambevski S, Denton CP on behalf of the SENSICIS trial investigators	Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression	RMD Open	9	e00285	2023
Nagahata K, Suzuki C, Takahashi H.	Spurious macrocytic anemia in a patient with systemic lupus erythematosus: cold agglutinin disease.	Clin Rheumatol	doi: 10.1007/s10067-023-06536-5		2023
Ishikawa M, Endo Y, Yamazaki S, Sekiguchi A, Uchiyama A, Motegi SI.	Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.	Journal of Dermatology	in press		2023

Wang W, Bale S, Wei J, Yalavarthi B, Bhattacharyya D, Yan JJ, Abdala-Valencia H, Xu D, Sun H, Marangoni RG, Herzog E, Berdnikovs S, Miller SD, Sawalha AH, Tsou PS, Awaji K, Yamashita T, Sato S, Asano Y, Tiruppathi C, Yeldandi A, Schock BC, Bhattacharyya S, Varga J	Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs.	Nat Commun.	13(1)	6358	2022
Ikawa T, Ichimura Y, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y	The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts.	J Invest Dermatol.	142(6)	1541-1551	2022
Yamamoto A, Saito T, Hosoya T, Kawahata K, Asano Y, Sato S, Mizoguchi F, Yasuda S, Kohsaka H	Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis.	Arthritis Rheumatol.	74(5)	860-870	2022
Ichimura Y, Ikei H, Konishi R, Zeniya M, Okai T, Nomura T, Negishi K, Okiyama N	Relevance of leukemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease.	Rheumatology (Oxford)	Online		2022
Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng RX, Otomo N, Kwon YC, Sheng Y, Sugano N, Hwang MY, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung WT, Huang H, Takahashi D, Lee SS, Wang M, Karino K, Shim SC, Zheng X, Miyamura T, Kang YM, Ye D, Nakamura J, Suh CH, Tang Y, Motomura G, Park YB, Ding H, Kuroda T, Choe JY, Li C, Niuro H, Park Y, Shen C, Miyamoto T, Ahn GY, Fei W, Takeuchi T, Shin JM, Li K, Kawaguchi Y, Lee YK, Wang YF, Amano K, Park DJ, Yang W, Tada Y, Lau YL, Yamaji K, Zhu Z, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y	Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study.	Ann Rheum Dis	81	1273-1280	2022
Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multicenter, randomized controlled trial	Rheumatology	61	4445-4454	2022
Watanabe A, Shima Y, Takahashi H, Akiyama Y, Koderia M, Jinnin M, Azuma N, Ishii K, Kumanogoh A	Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial.	Modern Rheumatology	roac116	1-7	2022
Bruni C, Buch MH, Djokovic A, De Luca G, Dumitru RB, Giollo A, Galetti I, Steelandt A, Bratis K, Suliman YA, Milinkovic I, Baritussio A, Hasan G, Xintarakou A, Isomura Y, Markousis-Mavrogenis G, Mavrogeni S, Gargani L, Caforio ALP, Tschöpe C, Ristic A, Plein S, Behr E, Allanore Y, Kuwana M, Denton CP, Furst DE, Khann D, Krieg T, Marcolongo R, Pope A, Distler O, Seferovic P, and Matucci-Cerinic M	Consensus on the assessment of Systemic Sclerosis-associated primary Heart Involvement: WSF/HFA guidance on screening, diagnosis, and follow-up assessment	J. Scleroderma Relat. Disord	In press		
Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, and Khanna D	Therapeutic approaches to systemic sclerosis: Recent approvals and future candidate therapies	Clin. Rev. Allergy Immunol	doi: 10.1007/s12016-021-08891-0	Online ahead of print	
Hughes M, Allanore Y, Baron M, del Galdo F, Denton CP, Frech T, Furst D, Galetti I, Dagna L, Herrick A, Kuwana M, Matucci-Cerinic P, McMahan Z, Murray C, Proudman S, and Matucci-Cerinic M	Proton pump inhibitors in systemic sclerosis, a reappraisal to optimise the fight against reflux	Lancet Rheumatol	4(11)	e795-e803	2022

Kuster S, Jordan S, Elhai M, Held U, Steigmiller K, Bruni C, Cacciapaglia F, Vettori S, Siegert E, Rednic S, Codullo V, Airo P, Braun-Moscovici Y, Hunzelmann N, Joao Salvador M, Riccieri V, Gheorghiu AM, Alegre Sancho JJ, Romanowska-Prochnicka K, Castellvi I, Kötter I, Truchetet ME, López-Longo FJ, Novikov PI, Giollo A, Shirai Y, Belloli L, Zanatta E, Hachulla E, Smith V, Denton C, Ionescu RM, Schmeiser T, Distler JHW, Gabrielli A, Hoffmann-Vold AM, Kuwana M , Allanore Y, Distler O, and EUSTAR collaborators	Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort	RMD Open	8(2)	e002477	2022
Isomura Y, Shirai Y, and Kuwana M	Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan	Rheumatology (Oxford)	61(11)	4491-4496	2022
Kakkar V, Assassi S, Allanore Y, Kuwana M , Denton C, Khanna D, and Del Galdo F	Type 1 interferon activation in SSC: a biomarker, a target or the culprit?	Opinion Rheumatol	34(6)	357-364	2022
Yomono K and Kuwana M	Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies	Rheumatology (Oxford)	61(9)	3677-3685	2022
Kuwana M , Saito A, Sakamoto W, Raabe C, and Saito K	Incidence rate and prevalence of systemic sclerosis and systemic-sclerosis-associated interstitial lung disease in Japan: analysis using Japanese claims databases	Adv. Ther	39(5)	2222-2235	2022
Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, Denton CP, Luppi F, Ruaro B, Della Casa F, De Luca G, Spinicci M, Zammarchi L, Tomassetti S, Caminati A, Cavigli E, Albanesi M, Melchiorre F, Palmucci S, Vegni V, Guiducci S, Moggi-Pignone A, Allanore Y, Bartoloni A, Confalonieri M, Cortese G, Dagna L, de Cobelli F, de Paulis A, Harari S, Khanna D, Kuwana M , Taliani G, Lavorini F, Miele V, Morana G, Pesci A, Vancheri C, Colagrande S, and Matucci-Cerinic M	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19	Rheumatology (Oxford)	61(4)	1600-1609	2022
Kuwana M , Allanore Y, Denton CP, Distler JHW, Steen VD, Khanna D, Matucci-Cerinic M, Mayes MD, Volkman ER, Miede C, Gahlemann M, Quaresma Lic M, Alves M, and Distler O	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score	Arthritis Rheumatol	74(3)	518-526	2022
Shirai Y, Kawami N, Iwakiri K, and Kuwana M	Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis	J. Scleroderma Relat. Disord	7(1)	57-61	2022
Bruni C, Buch MH, De Luca G, Djokovic A, Dumitru RB, Giollo A, Polovina M, Steeland A, Bratis K, Suliman YA, Milinkovic I, Baritussio A, Hasan G, Xintarakou A, Isomura Y, Markousis-Mavrogenis G, Tofani L, Mavrogeni S, Gargani L, Caforio ALP, Tschoepe C, Ristic A, Klingel K, Plein S, Behr E, Allanore Y, Kuwana M , Denton CP, Furst DE, Khann D, Krieg T, Marcolongo R, Galetti I, Seferovic P, and Matucci-Cerinic M	Primary systemic sclerosis heart involvement: a systematic literature review and preliminary consensus-based WSF/HFA definition	J. Scleroderma Relat. Disord	7(1)	24-32	2022
Sawamura S, Makino K, Ide M, Shimada S, Kajihara I, Makino T, Jinnin M, Fukushima S.	Elevated Alpha 1(I) to Alpha 2(I) Collagen Ratio in Dermal Fibroblasts Possibly Contributes to Fibrosis in Systemic Sclerosis.	Int J Mol Sci.	23(12)	6811	2022
Tabata K, Kaminaka C, Yasutake M, Matsumiya R, Inaba Y, Yamamoto Y, Jinnin M, Fujii T.	Forearm porphyrin levels evaluated by digital imaging system are increased in patients with systemic sclerosis compared with patients in pre-clinical stage.	Intractable Rare Dis Res.	11(1)	1-6	2022
Murayama K, Ikegami I, Kamekura R, Sakamoto H, Yanagi M, Kamiya S, Sato T, Sato A, Shigehara K, Yamamoto M, Takahashi H, Takano KI, Ichimiya S.	CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions.	Front Immunol	doi: 10.3389/fimmu.2022.941385.		2022
Utsunomiya A, Chino T, Kasamatsu H, Hasegawa T, Utsunomiya N, Luong VH, Matsushita T, Sasaki Y, Ogura D, Niwa SI, Oyama N, Hasegawa M.	The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF-β signaling.	Arthritis Res Ther.	24(1)	94	2022

Oyama N, Hasegawa M.	Lichen Sclerosus: A Current Landscape of Autoimmune and Genetic Interplay.	Diagnos-tics (Basel).	12(12)	3070	2022
Sawamura S, Makino K, Ide M, Shimada S, Kajihara I, Makino T, Jinnin M, Fukushima S.	Elevated Alpha 1(I) to Alpha 2(I) Collagen Ratio in Dermal Fibroblasts Possibly Contributes to Fibrosis in Systemic Sclerosis.	Int J Mol Sci.	23(12)	6811	2022
Endo Y, Kim J, Uchiyama A, Yasuda M, Hara K, Motegi SI	Spontaneous pneumomediastinum developed after steroid pulse therapy in diffuse cutaneous systemic sclerosis patient: A case report.	Journal of Dermatology	49(6)	e185-e186	2022
Saito S, Endo Y, Nishio M, Uchiyama A, Uehara A, Toki S, Yasuda M, Ishikawa O, Muro Y, Motegi SI.	Anti-polymyositis/Scl antibody-positive overlap syndrome of diffuse cutaneous systemic sclerosis, dermatomyositis, systemic lupus erythematosus, and antiphospholipid syndrome.	Journal of Dermatology	49(2)	294-298	2022
長谷川稔	全身性強皮症におけるB細胞とマクロファージの役割	RHEUMATOLOGYリウマチ科	69(1)	106-112	2023
嶋 良仁	抗interleukin-6受容体抗体トシリズマブによる治療	皮膚科	Vol.1(5)	658-664	2022
長谷川稔	血管変化を鋭敏に検出するキャピラスコピーの活用-膠原病診療において-	DERMATOLOGY 皮膚科	1(4)	517-524	2022
牧野雄成	【Geneticsとepigenetics】全身強皮症(解説)	皮膚科	2(6)	719-727	2022
牧野雄成、當眞嗣雅、立石 大、藤田美歌子、大塚雅巳、片岡良友	全身性強皮症の分子病態と治療薬創製(解説)	Bio Clinica.	37(9)	844-849	2022
牧野 雄成	特殊な全身性強皮症(generalized morphealike SSc、薬剤性、職業性)(解説)	皮膚科	1(5)	681-685	2022
牧野貴充、牧野雄成	【全身性強皮症-最新の話題-】臨床 レイノー現象、指尖潰瘍、毛細血管異常、石灰沈着(解説)	皮膚科	1(5)	612-617	2022
茂木精一郎	全身性強皮症	皮膚科の臨床	64(7)	1211-1225	2022
茂木精一郎	膠原病の顔の皮疹とその鑑別	皮膚科	1(1)	136-142	2022
茂木精一郎	全身性強皮症 最近の話題 血管障害の治療	皮膚科	1(5)	639-646	2022